Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2019 ASCO Annual Meeting but not presented at the Meeting, can be found online only.
Activity of osimetrinib/AZD9291 in pretreated patients (pts) with epidermal growth factor receptor mutant (EGFRmt) non-small cell lung cancer (NSCLC), according to EGFR mutations detected in circulating plasma DNA (ctDNA).
Metastatic Non-Small Cell Lung Cancer
Lung Cancer—Non-Small Cell Metastatic
2019 ASCO Annual Meeting
J Clin Oncol 37, 2019 (suppl; abstr e20608)
Author(s): Emmanouil Kontopodis, Jordana Nuria, Aliki Ntzifa, Panayiotis Katsaounis, Charalambos Haris Charalambous, Ioannis Boukovinas, Emily Tsaroucha, Amanda Psyrri, Anna Koumarianou, Michail Nikolaou, Nikolaos K. Kentepozidis, Rafael Rosell, Vassilis Georgoulias, Niki Karachaliou, Athanasios Kotsakis; University Hospital of Heraklion "Venizeleion", Heraklion, Greece; University Hospital Quiron Dexeus, Barcelona, Spain; Hellenic Oncology Research Group (HORG), Athens, Greece; Bank of Cyprus Onc Centre, Nicosia, Cyprus; Bioclinic Thessaloniki Medical Oncology Unit, Athens, Greece; 8th Department of Pulmonary Diseases, “Sotiria” General Hospital, Athens, Greece; Attikon University Hospital, Athens, Greece; Hematology-Oncology Clinic, Fourth Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Internal Medicine, Medical Oncology Unit, “Elena Venizelou” General Maternal Hospital of Athens, Athens, Greece; Dept. of Oncology, 251 Hellenic Airforce General Hospital, Athens, AZ, Greece; Department of Medical Oncology, University General Hospital of Larissa, Larissa, Greece
Background: Osimertinib is an irreversible EGFR tyrosine kinase inhibitor (TKI), selective for EGFR TKI-sensitizing mutations and the T790M resistance mutation. We sought to determine the activity of osimertinib after progression on EGFR TKIs in pts with T790-negative ctDNA. Methods: A multicenter phase II study (
|del19 (-)/ L858R (-)||del19 (+)||L858R (+)|
|Median PFS, months||12.8||5.4||5.3|
|Median OS, months||Not reached||12.9||12.4|